Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
This one-day study day will provide a practical update on bispecific antibodies in oncology, with a focus on how these treatments work, which patients may be suitable, and how healthcare teams can manage their toxicity profile safely and effectively.
The programme will cover the role of bispecific antibodies across haematological malignancies and solid tumours, with direct relevance to teams involved in myeloma care.
Key topics
Understand the mechanism of action of bispecific antibodies and their role across haematological malignancies and solid tumours.
Identify patient selection criteria and relevant biomarkers for bispecific antibody treatment.
Recognise and manage cytokine release syndrome, including clinical features, grading and evidence-based management.
Identify and manage neurological toxicities, including immune effector cell-associated neurotoxicity syndrome.
Apply practical approaches to managing bispecific antibody-related adverse events, including complex and rare toxicities.
Understand step-up dosing protocols, hospitalisation requirements and safe delivery considerations.
Strengthen nursing care and patient safety practices for people receiving bispecific antibody treatment.
Who is the event for?
This study day may be relevant to healthcare professionals involved in caring for people receiving immunotherapy, including consultant haematologists, oncology clinicians, clinical nurse specialists, pharmacists, advanced practitioners, academics involved in cancer research and the wider multidisciplinary team.
–
